These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 35183610)

  • 21. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
    Di Noia V; Pimpinelli F; Renna D; Campo F; Cosimati A; Torchia A; Marcozzi B; Massacci A; Pallocca M; Pellini R; Morrone A; Cognetti F
    Eur J Cancer; 2022 Nov; 176():164-167. PubMed ID: 36223679
    [No Abstract]   [Full Text] [Related]  

  • 23. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
    Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
    Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy.
    Podrazil M; Taborska P; Stakheev D; Rataj M; Lastovicka J; Vlachova A; Pohunek P; Bartunkova J; Smrz D
    Front Immunol; 2022; 13():892277. PubMed ID: 35669765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in patients with haematological diseases treated with anti-CD20 antibodies: An observational study.
    Nishikubo M; Shimomura Y; Maruoka H; Nasu S; Nishioka T; Sakizono K; Mitsuyuki S; Kubo T; Okada N; Nakagawa D; Kamijo K; Imoto H; Yamamoto R; Nagai Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Miyakoshi C; Doi A; Ishikawa T
    Br J Haematol; 2022 Jun; 197(6):709-713. PubMed ID: 35262920
    [No Abstract]   [Full Text] [Related]  

  • 27. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
    Broseta JJ; Rodríguez-Espinosa D; Rodríguez N; Mosquera MDM; Marcos MÁ; Egri N; Pascal M; Soruco E; Bedini JL; Bayés B; Maduell F
    Am J Kidney Dis; 2021 Oct; 78(4):571-581. PubMed ID: 34174364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.
    Mileto D; Fenizia C; Cutrera M; Gagliardi G; Gigantiello A; De Silvestri A; Rizzo A; Mancon A; Bianchi M; De Poli F; Cuomo M; Burgo I; Longo M; Rimoldi SG; Pagani C; Grosso S; Micheli V; Rizzardini G; Grande R; Biasin M; Gismondo MR; Lombardi A
    Emerg Microbes Infect; 2021 Dec; 10(1):2235-2243. PubMed ID: 34749573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
    Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
    EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients.
    Oyaert M; De Scheerder MA; Van Herrewege S; Laureys G; Van Assche S; Cambron M; Naesens L; Hoste L; Claes K; Haerynck F; Kerre T; Van Laecke S; Van Biesen W; Jacques P; Verhasselt B; Padalko E
    Front Immunol; 2022; 13():858399. PubMed ID: 35401575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Similar humoral immune responses in peritoneal dialysis and haemodialysis patients after two doses of the SARS-CoV-2 vaccine BNT162b2.
    Patecki M; Merscher S; Dumann H; Bernhardt W; Dopfer-Jablonka A; Cossmann A; Stankov MV; Einecke G; Haller H; Schlieper G; Behrens GM
    Perit Dial Int; 2022 Jan; 42(1):100-101. PubMed ID: 34753339
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273.
    Grunau B; Golding L; Prusinkiewicz MA; Asamoah-Boaheng M; Armour R; Marquez AC; Jassem AN; Barakauskas V; O'Brien SF; Drews SJ; Haig S; Lavoie PM; Goldfarb DM
    Microbiol Spectr; 2022 Apr; 10(2):e0270221. PubMed ID: 35254166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees.
    Jäger M; Sonnleitner ST; Dichtl S; Lafon E; Diem G; Walder G; Lass-Flörl C; Wilflingseder D; Posch W
    Front Immunol; 2022; 13():868361. PubMed ID: 35833113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
    Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
    Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis.
    Caocci G; Mulas O; Mantovani D; Costa A; Galizia A; Barabino L; Greco M; Murru R; La Nasa G
    Ann Hematol; 2022 Apr; 101(4):929-931. PubMed ID: 34302519
    [No Abstract]   [Full Text] [Related]  

  • 36. Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
    McKenzie DR; Muñoz-Ruiz M; Monin L; Alaguthurai T; Lechmere T; Abdul-Jawad S; Graham C; Pollock E; Graham R; Sychowska K; Seow J; Tremain C; Gousis C; Domingo-Vila C; Cooper J; Vidler J; Owczarczyk K; Swampillai A; Kristeleit H; Malim MH; Fields P; Patten PEM; Papa S; North BV; Tree T; Doores KJ; Hayday AC; Irshad S
    Cancer Cell; 2021 Nov; 39(11):1445-1447. PubMed ID: 34678151
    [No Abstract]   [Full Text] [Related]  

  • 37. Delayed Humoral Response After 2 Doses of the BNT162b2 Vaccine in a Belgian Kidney Transplant Cohort.
    Georgery H; Devresse A; Saad Albichr I; Lucas S; Yombi JC; Belkhir L; De Greef J; Scohy A; Kabamba B; Goffin E; Kanaan N
    Transplantation; 2022 Mar; 106(3):e192-e193. PubMed ID: 34519679
    [No Abstract]   [Full Text] [Related]  

  • 38. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R
    J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation.
    Yeshurun M; Pasvolsky O; Shargian L; Yahav D; Ben-Zvi H; Rubinstein M; Sela-Navon M; Wolach O; Raanani P; Rozovski U
    Clin Microbiol Infect; 2022 Feb; 28(2):303.e1-303.e4. PubMed ID: 34715348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.